Tandem Diabetes Care closes IPO; Honda starts tests on rehab exoskeleton;

@FierceMedDev: ResMed wins German court injunction against two respiratory device patent rivals. More | Follow @FierceMedDev

@MarkHFierce: J&J's $2.5B settlement addresses thousands of lawsuits over faulty metal hip implants but many will remain in play. Story | Follow @MarkHFierce

> Tandem Diabetes Care ($TNDM) has officially closed its initial public offering, which involved more than 9.2 million shares at $15 a piece. Item

> Honda is pursuing its first large-scale clinical trial of a battery and motor-powered exoskeleton designed to help patients improve their mobility in a physical rehabilitation setting. Story

> Cutting-edge camera maker Lytro raised an additional $40 million in funding to fuel a redesigned device featuring technology the company touts as having appeal to medical-device makers. Story

> The FDA hit devicemaker Avacen with a warning letter for a number of quality system violations involving its thermal exchange system product. Warning letter

> A number of manufacturers have linked up to develop a more streamlined and safer manufacturing process for implantable medical devices. Item

Biotech News

@FierceBiotech: Clovis bets up to $420M on targeted cancer drug. News | Follow @FierceBiotech

@JohnCFierce: Great talk with Missouri Bio and KansasBio today. About half read Fierce on their cell phones. New day and new media. | Follow @JohnCFierce

@DamianFierce: Meet Rebecca Friend, publisher of the FierceBiotech family of publications. More | Follow @DamianFierce

@EmilyMFierce: News about Art Levinson's Calico breaks on... Google+? Story | Follow @EmilyMFierce

>  Argos rakes in $17.5M more to wrap up PhIII for cancer drug. More

>  Moderna nails $110M to get mRNA tech into the clinic. Article

>  BioMarin skates through FDA panel for rare disease drug. News

>  Google's Calico poaches Roche guru Barron to steer R&D. Article

Pharma News

@FiercePharma: Best-read new news Tuesday: Can Teva find a partner to save it from itself? Story | Follow @FiercePharma

@EricPFierce: GSK continues to lead with continuous processing. Will use technology at $136.5 million plant in India. More | Follow @EricPFierce

@CarlyHFierce: Roche's Kadcyla approved in the EU for advanced HER2-positive breast cancer. Release | Follow @CarlyHFierce

> Ex-Teva chief Jeremy Levin to MBA grads: Anyone have a job for me? Story

> Daiichi clot-fighter aces study, but can it compete with Pradaxa, Xarelto and Eliquis? Article

Drug Delivery News

@MichaelGFierce: Delivery guru Robert Langer discusses nanomeds, up-and-coming ventures, new frontiers. Editor's corner | Follow @MichaelGFierce

> Unilife signs $80M deal to supply Hikma with prefilled syringes. Story

> FDA allows pivotal trial of Actinium's armed-antibody isotope delivery. Article

> Svelte begins pivotal trial for drug-eluting stent. Report

> Study: Genes delivered directly to heart stymie heart failure. More

> Dual-wave approach clears path for cancer drug delivery. Story

> Oramed wins European patent for insulin pill tech. Item

Diagnostics News

> GenapSys nails down $37M to advance next-generation gene sequencing tech. Article

> Trovagene pledges results, in part, from cancer urine test launch. Report

> Houston Methodist-led team shows potential of early breast cancer blood Dx. More

> Atossa makes headway in getting breast cancer test back to market. Article

> FDA OKs 4 Illumina next-generation sequencing devices. Report

> Johns Hopkins approach shows promise in early dementia diagnosis. Item

Suggested Articles

In an SEC filing, Baxter International disclosed that it may have overstated its income over multiple years, inflating it by about $276 million.

The FDA has given Grail a green light to conduct the interventional study, and it has begun enrolling participants through the company’s R&D partners.

Coronavirus may not require a front-line battle yet in certain places, but it’s still taxing public health officials preparing for a potential crisis.